Trials in Philadelphia, Pennsylvania
Here are the top 10 medical studies for breast cancer in Philadelphia, Pennsylvania
Popular Filters
Phase 3 Trials
Monoclonal Antibodies
Atezolizumab + Standard Therapy for HER2-Positive Breast Cancer
Recruiting1 awardPhase 3
Newark, Delaware
This trial is studying how well paclitaxel, trastuzumab, and pertuzumab with or without atezolizumab works in treating patients with breast cancer that has spread to other parts of the body (metastatic).
Endocrine Therapy
Palbociclib + Endocrine Therapy for Breast Cancer
Recruiting2 awardsPhase 3
Newark, Delaware
This trial is testing whether adding the drug palbociclib to standard hormone therapy can improve treatment for patients with a specific type of early breast cancer. The targeted patients have hormone receptor-positive and HER2-negative breast cancer. Palbociclib works by blocking proteins that help cancer cells grow, potentially making the hormone therapy more effective.
Chemotherapy
Chemotherapy + HER2-Targeted Therapy With or Without Hormone Therapy for Breast Cancer
Recruiting4 awardsPhase 3
Hot Springs, Arkansas
This trial is studying a combination of drugs given with or without hormone therapy to see how well they work in treating patients with hormone receptor-positive, HER2-positive breast cancer.
Hormone Therapy
Fulvestrant + Anastrozole for Breast Cancer
Recruiting4 awardsPhase 3
Birmingham, Alabama
This trial is testing whether neoadjuvant endocrine therapy with fulvestrant or the combination of anastrozole and fulvestrant is better than anastrozole when given before surgery to shrink the cancer and stop it from growing.
Trials With No Placebo
XL092 + Immunotherapy for Cancer
Recruiting1 awardPhase 1
Philadelphia, Pennsylvania
This trial is testing a new drug called XL092 by itself and with two other drugs, atezolizumab and avelumab. It targets patients with advanced solid tumors who may not respond to current treatments. XL092 aims to stop cancer cells from growing, while atezolizumab and avelumab help the immune system fight the cancer. Atezolizumab is approved for various cancers, including breast and urothelial carcinoma, and has shown efficacy in combination with chemotherapy.
Endocrine Therapy
Palbociclib + Endocrine Therapy for Breast Cancer
Recruiting2 awardsPhase 3
Newark, Delaware
This trial is testing whether adding the drug palbociclib to standard hormone therapy can improve treatment for patients with a specific type of early breast cancer. The targeted patients have hormone receptor-positive and HER2-negative breast cancer. Palbociclib works by blocking proteins that help cancer cells grow, potentially making the hormone therapy more effective.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.